1. Introduction {#sec1}
===============

Cancer is one of the major concerns in the medical field as it causes increasing number of deaths day by day.^[@ref1]^ In the past decades, there have been numerous anticancer drugs synthesized. However, tumor recurrence and the adverse effects of the drugs because of toxic intolerance are the key problems in the treatment of cancer. Thus, there is an urgent and desperate need of finding anticancerous drug molecules with negligible side effects and high efficacy. The naturally occurring products have received special attention toward the preparation of novel cancer preventives and therapeutic agents.^[@ref2]−[@ref4]^ Particularly, more natural products were identified with potential anticancer activity.^[@ref5],[@ref6]^ In the present work, virtual screening and suitability of anacardic acid (AA) derivatives that inhibit the anticancer target cyclin-dependent kinase 2 (PDB ID: 1W98) were studied. AA originates from the nutshells of *Anacardium occidentale* (cashew)^[@ref7]^ and found to act as an antitumor, antibiotic, antioxidant, and gastroprotective agent.^[@ref8]^ It is a combination of numerous closely related organic compounds, each consisting of salicylic acid substituted with an alkyl chain. In addition, it is used as a synthon for the production of a variety of biologically active compounds and a capping agent for the development of nanomaterials.^[@ref9]^ For the treatment of the most serious pathophysiological disorders like cancer, oxidative damage, inflammation, and obesity, AA and its derivatives have been strongly supported as therapeutic agents.^[@ref7]^ Recent studies show that AA derivatives exert their action in treating ovarian cancer, prostate cancer, breast carcinoma, and lung carcinoma through various mechanisms.^[@ref10]−[@ref13]^ AA acts as a potential inhibitor of histone acetyltransferase activity and sensitizes tumor cells to ionizing radiation.^[@ref13]^ With the anticipation that AA can be eventually applied in the medicinal industry after successful preclinical trials, Xiu et al. have investigated the role of AA in cancer.^[@ref14]^

However, during the clearance of the molecule under clinical trials, wastage of the drugs and human efforts is unavoidable. In this regard, computation methods were developed to predict the human pharmacokinetic properties. With different levels of complexity for the screening of large data set compounds, a variety of useful in silico ADME (absorption, distribution, metabolism, excretion) models have been established. Nowadays, the in silico tools are faster, simpler, and more cost-effective than transitional investigational procedures.^[@ref15]^ At present, because of the toxicity or lag of optimal pharmacokinetics properties, large attrition rates of preclinical and clinical candidates were observed in pharmaceutical industry. It is possible for medicinal chemists to control the pharmacokinetic and toxicity properties of a molecule through the structural modifications.^[@ref16]^ Hence, in the present work, physicochemical, ADME attributes and in silico toxicity^[@ref17]^ of 100 AA derivatives were evaluated, and the results were compared with well-known anticancer drugs. The study would definitely help to identify the suitable oral AA-based drug molecules based on the abovementioned properties and their binding activities with the target cyclin-dependent kinase 2. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} shows the schematic diagram of the work done in which the selection of compounds and screening methods were illustrated.

![Flowchart illustrating the selection of AA derivatives, screening process, and their interactions with the target (PDB ID: 1W98).](ao9b04398_0001){#fig1}

2. Materials and Methods {#sec2}
========================

One of the main causes of drug development termination is poor pharmacokinetic properties. Less or no toxicity, good oral bioavailability, and optimum values of physicochemical properties are the key parameters for the discovery of anticancer drugs. In the present work, 100 AA derivatives were selected from the previous literatures^[@ref8]−[@ref14],[@ref18],[@ref19]^ for the evaluation of their pharmacokinetic properties. Among these, the derivatives AA1--AA25 were obtained by alkyl chain modifications, whereas AA26--AA50 were obtained by modifying both the alkyl chain and functional groups ([Figures S1 and S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf)). AA51--AA100 derivatives were obtained by introducing functional groups like hydroxyl (−OH) and carboxylic (−COOH) groups ([Figures S3 and S4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf)). A complete list of AA derivatives used in this study is depicted in [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf), whereas the name and structures of the finally scrutinized molecules are depicted in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and the physicochemical properties of these derivatives are listed in [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}--[6](#tbl6){ref-type="other"}.

###### Names and Structures of the Screened Out Derivatives

![](ao9b04398_0005){#gr5}

###### Important Computed Physicochemical Properties of the Screened Out AA Derivatives[a](#t2fn1){ref-type="table-fn"}

  AA derivatives   MW       *n*~Rot~   HBA   HBD   TPSA     *M* log *P*   Ali log *S*   MR
  ---------------- -------- ---------- ----- ----- -------- ------------- ------------- --------
  AA11             328.4    9          4     2     66.76    3.66          --6.79        95.4
  AA12             302.32   7          5     2     75.99    2.41          --5.19        82.51
  AA16             264.36   9          3     2     57.53    3.55          --6.62        78.85
  AA20             274.27   4          5     4     97.99    1.91          --4.88        73.73
  AA21             242.27   4          3     2     57.53    3.06          --4.76        69.68
  AA22             290.27   4          6     5     118.22   1.37          --4.94        75.75
  AA23             220.26   3          3     2     57.53    2.39          --5.01        62.31
  AA24             238.28   7          4     3     77.76    1.93          --4.32        65.59
  AA25             264.32   9          4     2     74.6     2.37          --5.12        74.24
  AA33             266.33   9          4     2     66.76    2.45          --4.8         74.71
  AA34             294.39   11         4     2     66.76    2.95          --5.92        84.33
  AA72             426.59   5          3     1     34.15    4.21          --5.3         127.19
  AA75             388.51   3          4     0     52.83    4.4           --5.08        109.46
  AA95             262.34   1          3     0     35.53    3.16          --5.13        75.91
  AA96             260.33   1          3     0     35.53    3.08          --4.83        76.23
  AA97             276.33   1          4     0     48.06    2.31          --3.69        74.88
  AA98             276.33   1          4     0     52.6     2.23          --3.54        76.11

Optimal range: molecular weight (MW) ≤ 600, lipophilicity log or Moriguchi octane--water partition coefficient (*M* log *P*) ≤ 5, aqueous solubility descriptor (Ali log *S*) ≤ 0, hydrogen-bonded acceptor (HBA) ≤ 10, hydrogen-bonded donor (HBD) ≤ 5, topological polar surface area (TPSA) ≤ 150 Å^2^, number of rotatable bonds (*n*~Rot~) ≤ 10, and molar refractivity (MR) ≤ 155.

###### Important Computed ADMET Properties of the Screened Out AA Derivatives[a](#t3fn1){ref-type="table-fn"}

  AA derivatives   Caco2 permeability (log *P*~app~ in 10^--6^ cm/s)   intestinal absorption (human) (% absorbed)   *V*~Dss~ (human) (log *L*/kg)   fraction unbound (human)   P-gp substrate (yes/no)
  ---------------- --------------------------------------------------- -------------------------------------------- ------------------------------- -------------------------- -------------------------
  AA11             0.684                                               98.43                                        --1.596                         0.04                       no
  AA12             1.07                                                100                                          --1.485                         0.125                      yes
  AA16             1.25                                                95.899                                       --1.496                         0.232                      no
  AA20             0.873                                               56.592                                       --0.398                         0.199                      yes
  AA21             1.249                                               96.995                                       --1.12                          0.089                      yes
  AA22             0.305                                               46.001                                       --0.308                         0.153                      yes
  AA23             1.222                                               89.976                                       --0.231                         0.206                      no
  AA24             0.888                                               95.688                                       --1.723                         0.41                       no
  AA25             0.92                                                97.934                                       --1.641                         0.29                       no
  AA33             1.127                                               91.257                                       --0.035                         0.166                      yes
  AA34             1.084                                               90.567                                       0.014                           0.113                      yes
  AA72             1.314                                               97.793                                       1.026                           0.007                      yes
  AA75             1.568                                               100                                          --0.158                         0                          no
  AA95             1.031                                               96.303                                       0.107                           0.268                      no
  AA96             1.778                                               94.729                                       0.161                           0.202                      no
  AA97             1.386                                               95.664                                       0.083                           0.225                      no
  AA98             1.351                                               97.828                                       --0.082                         0.249                      no

Caco-2 cell permeability (log *P*~app~ in 10^--6^ cm/s \>0.09); intestinal absorption (human), % absorbed (\>30); *V*~Dss~ (human) (log *L*/kg) (low if \<−0.15 and high if \>0.45).

###### Important Computed Physicochemical Properties of Some Marketed Anticancer Drugs

  Drugs                   MW       *n*~Rot~   HBA   HBD   TPSA     *M* log *P*   Ali log *S*   MR
  ----------------------- -------- ---------- ----- ----- -------- ------------- ------------- --------
  Abemaciclib             502.63   7          7     1     75       2.87          --5.38        154.18
  Ambochlorin             293.37   4          4     0     78.29    1.71          --3.3         83.81
  Anastrozole             276.21   5          6     1     74.92    2.03          --4.6         64.19
  Capecitabine            317.22   3          7     1     95.23    1.43          --3.63        77.26
  Erivedge (Vismodegib)   421.3    5          4     1     84.51    3.24          --5.31        107
  Flutamide               499.61   11         5     2     87.55    1.71          --5.25        150.43
  Nelarabine              359.35   8          8     3     122.91   0.53          --2.71        85.25
  Nilutamide              167.19   0          3     2     119.28   --0.96        --2.31        43.34
  Osimertinib             297.27   3          8     4     148.77   --2.12        --1.61        69.17
  Purinethol              304.21   9          2     1     40.54    3.29          --2.17        81.01

###### Important Computed ADMET Properties for Some Marketed Anticancer Drugs

  Drugs                   Caco2 permeability (log *P*~app~ in 10^--6^ cm/s)   intestinal absorption (human) (% absorbed)   *V*~Dss~ (human) (log *L*/kg)   fraction unbound (human)   P-gp substrate (yes/no)
  ----------------------- --------------------------------------------------- -------------------------------------------- ------------------------------- -------------------------- -------------------------
  Abemaciclib             1.38                                                88.951                                       0.535                           0.285                      yes
  Ambochlorin             1.069                                               98.691                                       --0.03                          0.138                      no
  Anastrazole             0.869                                               88.757                                       --0.118                         0.029                      yes
  Capecitabine            1.2                                                 87.504                                       --0.423                         0.097                      no
  Erivedge (Vismodegib)   1.074                                               94.883                                       --0.075                         0.127                      no
  Flutamide               0.811                                               95.992                                       1.093                           0.145                      yes
  Nelarabine              0.319                                               51.344                                       --0.073                         0.424                      no
  Nilutamide              1.207                                               84.051                                       --0.421                         0.636                      yes
  Osimertinib             --0.023                                             48.895                                       --0.013                         0.841                      no
  Purinethol              1.439                                               92.268                                       --0.165                         0.117                      no

###### Computed Safety End Points for AA Derivatives

  Der.   CYP2D6 inhibitor   CYP3A4 inhibitor   total clearance   renal OCT2 substrate   AMES toxicity   hERG I inhibitor   oral rat acute toxicity (LD~50~)   oral rat chronic toxicity (LOAEL)   hepatotoxicity   skin sensitization
  ------ ------------------ ------------------ ----------------- ---------------------- --------------- ------------------ ---------------------------------- ----------------------------------- ---------------- --------------------
  AA11   no                 no                 0.658             no                     no              no                 2.901                              2.237                               no               no
  AA12   no                 no                 0.544             no                     no              no                 2.919                              2.074                               no               no
  AA16   no                 no                 1.312             no                     no              no                 2.53                               2.759                               no               no
  AA20   no                 no                 0.505             no                     no              no                 2.353                              1.774                               no               no
  AA21   no                 no                 0.656             no                     no              no                 2.673                              2.888                               no               no
  AA22   no                 no                 0.333             no                     no              no                 2.317                              3.039                               no               no
  AA23   no                 no                 0.551             no                     no              no                 2.432                              2.207                               no               no
  AA24   no                 no                 0.672             no                     no              no                 2.324                              2.445                               no               no
  AA25   no                 no                 1.265             no                     no              no                 2.554                              2.247                               no               no
  AA33   no                 no                 0.828             no                     no              1.987              2.141                              no                                  no               no
  AA34   no                 no                 1.488             no                     no              no                 2.097                              2.192                               no               no
  AA72   yes                no                 0.725             yes                    no              no                 2.054                              1.463                               yes              no
  AA75   no                 no                 0.67              no                     no              no                 1.829                              2.357                               yes              no
  AA95   no                 no                 1.351             no                     no              no                 2.012                              2.044                               no               no
  AA96   no                 no                 0.619             no                     no              no                 2.228                              1.871                               no               no
  AA97   no                 no                 1.174             no                     no              no                 2.15                               1.701                               no               no
  AA98   no                 no                 0.645             no                     no              no                 2.231                              1.756                               no               no

The ADME-related physicochemical properties of 100 AA derivatives including the marketed anticancer drugs were predicted by the Swiss ADME online Web server.^[@ref20]^ Two-dimensional structures were drawn with the help of Cambridge software, that is, ChemDraw Pro, version 12.0. A simplified molecular input line entry system of all AA derivatives was generated with the help of an online tool, that is, Swiss ADME. The physicochemical properties, lipophilicity and solubility, of the derivatives were considered for the analysis.^[@ref21]^

In addition, the BOILED-Egg model of the molecules was predicted to reveal the capability of gastrointestinal (GI) absorption and permeability of the blood--brain penetration barrier.^[@ref22]^ The cutoff values of the physicochemical properties were set by certain rules, that is, Lipinski's rule of five (ROF), bioavailability score, Ghose's, and Veber's rules.^[@ref23]−[@ref25]^ For drug-likeliness, the molecular parameters such as MW (molecular weight), HBD (hydrogen bond donor), HBA (hydrogen bond acceptor), log *P* (lipophilicity log), log *S* (aqueous solubility), TPSA (topological polar surface area), MW, *n*~Rot~ (number of rotatable bonds), and MR (molar refractivity) were evaluated. For predicting the aforesaid properties, Swiss vector machine algorithm^[@ref26]^ is used.

There are two more important parameters, that is, plasma proteins (*F*~u~) and volume of distribution (*V*~Dss~), which help in the determination of the distribution of derivatives. The absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of all AA derivatives were analyzed through the online available tool pkSCM (<http://bleoberis.bioc.cam.ac.uk/pkcsm/>).^[@ref27]^

In silico data corresponding to the major human cytochrome P450 (CYP) isoforms involved in drug metabolism, such as CYP2C9, CYP2D6, and CYP3A4, were also generated. To determine the excretion routes of AA derivatives, the total clearance and renal OCT2 substrate were predicted quantitatively. In drug attrition, the safety profile of the derivatives comes under major factors.^[@ref28]^ As per pharmacokinetic analysis, we assess some of the major toxicity end points of all derivatives. Moreover, certain safety parameters such as LD50, hepatotoxicity, skin sensitization, cellular toxicity, and hERG liability (inhibition of dofetilide binding) were also evaluated.

After the pharmacokinetic evaluation of all the AA derivatives, 17 AA molecules were chosen based on the cutoff values set by Lipinski's ROF, bioavailability score, Ghose's, and Veber's rules. Finally, the chosen molecules were docked with cyclin-dependent kinase 2 to evaluate their binding affinities and active binding residues. For this process, the SwissDock docking server (<http://www.swissdock.ch>) is used. The preparation of the target for docking was done by UCSF chimera. Various docking parameters such as full fitness (FF, kcal/mol), total number of clusters, cluster rank, Gibbs free energy (Δ*G*), hydrogen bonding, deltaGligsolvpol, and so forth were analyzed.

3. Results and Discussion {#sec3}
=========================

3.1. Structural and Physicochemical Properties {#sec3.1}
----------------------------------------------

The main emphasis has been on defining the physicochemical property rules for the derivatives to reduce attrition and increase the likelihood of them at various stages of anticancer drug development. Based on the gold standards and earlier published research on various oral bioavailability rules, 100 AA derivatives were evaluated together with 10 marketed anticancer drugs against the key parameters of physicochemical properties, that is, lipophilicity, log *P*, MW, TPSA, HBD, HBA, *n*~Rot~, and aqueous solubility (log *S*).^[@ref23]−[@ref25]^ All physicochemical properties are depicted in [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf).

The MW range of AA1--AA25 derivatives varies from 220 to 376, AA26--AA50 derivatives varies from 264 to 518, and AA51--AA80 derivatives varies from 388 to 598, whereas the MW range for AA81--AA100 is much broader and varies from 260 to 597. The *M* log *P* value of AA1--AA25 derivatives varies from 1.4 to 6, AA26--AA50 derivatives varies from 2.4 to 5.3, and AA51--AA80 derivatives varies from 3.1 to 7.5, whereas AA81--AA100 derivatives show values varying from 2.2 to 6.4. There were no significant differences in the log *P* values among the four groups, although the alkyl-modified derivative set AA1--AA25 had a lower span of log *P* values; meanwhile, each set shows predicted values of some derivatives which are higher than the cutoff value set by the Lipinski rule, RO5 ≤ 4.15. This reflects the fact that molecules with out-of-range values of log *P* are poorly soluble in fats, oil, lipids, and nonpolar solvents. The predicted polarity (TPSA) ranges from 56 to 157 Å^2^ for AA1--AA25 derivatives, 20 to 120 Å^2^ for AA26--AA50 derivatives, 14 to 77 Å^2^ for AA51--AA80 derivatives, and 35 to 115 Å^2^ for AA81--AA100 derivatives. According to the cutoff values set for TPSA (≤140 Å^2^) by Veber et al.,^[@ref24]^ 95% of the AA derivatives reported in this study are likely to have high probability of oral bioavailability. A minimal number of HBDs ranging from 0 to 5 was found in the AA derivatives.

All the 100 derivatives of AA in this study satisfy the rule of Lipinski, HBA \< 10. One important parameter for the oral bioavailability is "MR" described by the Ghose filter.^[@ref25]^ According to Lipinski's rule, the value of MR should lie between 40 and 130^[@ref23]^ for drug-likeness. The derivatives AA1--AA50 show that all the predicted values fall within the range as described by the Ghose filter rule, whereas the derivative set AA50--AA100 shows 30% violation.

In order to accurately access drug-likeness, Lipinski's RO5, Ghose filter, Vebers's, Egan's, and Muegge's rules are compared with certain marketed drugs. The detailed data set of all AA derivatives with the violation of rules is shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}.

![Results of AA derivatives against different violations.](ao9b04398_0002){#fig2}

The graph shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}a reveals that most of the derivatives show one violation of each rule, and few structures viz. AA11, AA12, AA16, and AA20--AA25 did not show any violation. Hence, they can be provisionally approved for preclinical trials. The structures that show three violations of the Muegge and Ghose filters must be excluded from further preclinical processes. In [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}b, it is clear that the structures AA33 and AA34 did not show any violation, and most of the derivatives violate more than one rule for each filter. The Lipinski RO5 rule graph as shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}c,d suggests that the compounds AA72, AA75, and AA95--AA98 can be subjected for further preclinical trials. Out of 100 investigated compounds, only 17 compounds fall within the allowed range of physicochemical properties and satisfy all the key parameters of physicochemical properties.

3.2. Comparison of Physicochemical Properties of AA Derivatives with Marketed Anticancer Drugs {#sec3.2}
----------------------------------------------------------------------------------------------

Our analysis shows that the optimal property ranges (covering 100 AA derivatives) are 200 \< MW ≤ 600, 1 \< *M* log *P* ≤ 5, −6 ≤ Ali log *S* ≤ 0, 2 ≤ HBA ≤ 10, 1 ≤ HBD ≤ 5, 50 ≤ TPSA ≤ 150 Å^2^, 0 ≤ *n*~Rot~ ≤ 10, and 40 ≤ MR ≤ 155. They may be very helpful in the prospective design of anticancer molecules. According to the RO5 rule, the key parameters of physicochemical properties showed better results as compared to the marketed anticancer drugs. The poor biopharmaceutical properties of the molecules, viz. poor aqueous solubility and slow dissolution rate resulted in poor oral bioavailability. In general, poor aqueous solubility is connected to high lipophilicity, and hydrophilic derivatives are connected to poor permeability, which means low absorption. Hence, ionization constants, solubility, and lipophilicity measurements are helpful in the high-throughput drug discovery paradigm. The relationship between lipophilicity and pharmacokinetic properties is explained in in silico studies.^[@ref29],[@ref30]^ In the present work, quantitative analysis shows that the finally scrutinized AA derivatives were predicted to have a higher optimum range of 13.18 for *M* log *P*, whereas the predicted values of *M* log *P* for the marketed anticancer drugs are in the range 2.12--5.6. [Tables S1 and S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf) depict the physicochemical and ADMET parameters of all the selected molecules.

3.3. BOILED-Egg for Prediction of GI Absorption and Brain Penetration {#sec3.3}
---------------------------------------------------------------------

In the drug development process, GI absorption and blood--brain barrier (BBB) penetration play an important role. The BOILED-Egg model helps in the computation of polarity and lipophilicity of derivatives as it gives datasets with accuracy, speed, and clear graphical outputs.^[@ref22]^ This model helps in drug development by filtering the chemical libraries.

In the BOILED-Egg model, the high probability of passive absorption of the GI tract is represented by the white region, whereas the yellow region (yolk) represents the high probability of the BBB penetration. In addition, the blue color indicator of the molecule shows that the molecule is actively effluxed by P-glycoprotein, represented as (PGP^+^), whereas the red color indicator shows the nonsubstrate of P-gp, represented as (PGP^--^).

The analysis predicts that the molecules AA1--AA25 ([Figure S5a](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf)) show high GI absorption, with nearly 40% of the molecules also exhibiting BBB penetration, and all of them are predicted as the nonsubstrates of P-gp (PGP^--^); 90% of the molecules AA26--AA50 ([Figure S5b](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf)) show GI absorption, with nearly 40% of them also exhibiting BBB penetration. The BOILED-Egg plot of all the AA derivatives is presented in [Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf). The predicted results of the derivatives AA51--AA80 ([Figure S5c](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf)) consisting of benzamide and benzyl amine are shown. All the benzamide-based AA molecules and most of the benzyl amine-substituted AA derivatives show low GI absorption, and they do not exhibit significant BBB permeability. Most of the derivatives in the molecule set AA5--AA80 are P-gp substrates. The prediction of the BOILED-Egg results of the molecule set AA81--AA100 ([Figure S5d](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf)), which includes thiazole, imidazole, oxazole, sildenafil, dihydropyridine, and macrolide AA derivatives, shows low GI absorption, and they do not exhibit BBB permeation. The BOILED-Egg model prediction of GI absorption and BBB permeation of the finally scrutinized 17 AA derivatives is presented in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}.

![BOILED-Egg model of AA derivatives.](ao9b04398_0003){#fig3}

3.4. Prediction of ADMET and Related Properties {#sec3.4}
-----------------------------------------------

For the development of a drug, the derivatives should have good ADMET profile. With the help of significant advancement in high-throughput in vitro ADME, computational scientists were able to predict the potential liabilities, that is, susceptibility to efflux transporters, low permeability, and so forth, of derivatives, which are associated with new potential derivatives. For the assessment of Caco2 cell permeability, P-gp efflux liability, and human intestinal absorption of anacardic derivatives, we have evaluated the ADME properties (in silico profiling).^[@ref32]^ On the basis of the ADME model, we can evaluate the permeability of a molecule, whether it is low or high. The permeability, that is, log *P*~app~ (10^--6^ cm/s) rate, is considered to be high if log *P*~app~ \> 0.9 and considered to be low if log *P*~app~ \< 0.9. The Caco2 cell permeability of AA derivatives is mentioned in [Table S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf).

Of the AA derivatives, 80% show high log *P*~app~ values. Similar results were also analyzed in the assessment of P-gp efflux liabilities of AA derivatives. The assessment of P-gp efflux liabilities was done with the help of preADMET's \[<https://preadmet.bmdrc.kr/>\] P-gp substrate model. Only 25% of anacardic derivatives were found as P-gp efflux substrates. The predicted ADMET parameters of AA derivatives are listed in [Table S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf). For the achievement of an optimal clinical drug/derivative, a derivative should have high log *P*~app~ and low P-gp efflux liability.

In addition, we have calculated the total human intestinal absorption percentage (%). For the GI tract dissolution and stability, a systematic oral dosage should have pH 1--2 in fasted state and 3--7 in fed state in stomach, including a neutral environment of small intestine, that is, pH 4.4--6.6.^[@ref32]^ The human intestinal absorption percentage (%) of the AA derivatives was analyzed with the help of an online server tool, pkCSM.^[@ref27]^ Except two AA molecules (AA99 and AA100), the rest of the other AA derivatives shows good human intestinal absorption. The predicted human intestinal absorption percentage (%) values for all the AA molecules are listed in [Table S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf).

In plasma, almost all drugs exist in equilibrium between the bound and unbound states with serum proteins at different affinities. Only an unbound drug can show interactions with anticipated molecular targets.^[@ref22]^ Therefore, the efficiency of a drug is affected by the binding efficacy of the drug with whole blood proteins. With the help of the predictive model of pkCSM, we have evaluated the fraction unbound (*F*~u~) and steady-state volume of distribution (*V*~Dss~) of 100 AA derivatives. *V*~Dss~ is a key parameter, which helps in suggestion for the total dose of a drug. The predicted values of *F*~u~ and *V*~Dss~ of all AA derivatives are listed in [Table S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf).

For drug designing and screening of new chemical drugs, pharmaceutical industries use in silico studies for early prediction.^[@ref33]^ For evaluating AA derivatives as anticancer drugs, we have evaluated the toxicity end points with the help of the pkCSM tool. The toxicity end points consist of the inhibition of cytochrome P450 (CYPs) monooxygenase enzymes.^[@ref34]^ AMES toxicity, LD50 (lethal rat acute toxicity), hepatotoxicity, skin sensitization, and inhibition of hERG potassium ion channel effects are determined for the evaluation of drug--drug interactions (DDIs).^[@ref35]^ The toxicity data sets of all AA derivatives are listed in [Table S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf). With the help of pkCSM, inhibitions of CYP2D6 and CYP3A4 were qualitatively predicted and the results are depicted in [Table S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf). Out of 100 AA derivatives, 80% AA derivatives were evaluated as noninhibitors of CYP3A4, and only two AA derivatives show inhibition against CYP2D6. After the evaluation of these parameters, drug excretion and drug metabolism were evaluated. With the prior knowledge of metabolic pathways of drugs, one can easily predict DDIs, pharmacokinetics, and toxicities.^[@ref36]^ Here, our primary concern is the inhibition of CYP3A4, which helps in finding out the correlation with increasing MW and log *P*.^[@ref37]^ Inhibition of CYP3A4 is related to issues with DDIs and clearance. The total clearance of 100 AA derivatives was measured, which is a combination of hepatic and renal clearance, and is listed in [Table S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf).

The major evaluation that emerged from these data was that the derivatives showing clog *P* \< 3 and TPSA \> 75 Å^2^ were 2.5 times more nontoxic, whereas derivatives showing high lipophilicity (clog *P* \> 3) and low polar surface area (TPSA \< 75 Å^2^) are considered to be highly toxic in short-term animal studies. Hence, we have evaluated the lipophilicity of AA derivatives. Lipophilicity with small polar functionalities has high chances of becoming toxic. From the evaluation, it is revealed that toxicity occurs when log *P* \> 3; on the other hand, the value of TPSA shows very little or no influence on the drug toxicity. Hence, it is clear that the early prediction of log *P* and TPSA is very helpful in the drug designing and development process in order to avoid wastage of chemicals.

Establishment of meaningful correlations between the physicochemical properties and ADMET properties of AA derivatives might be useful for future anticancer drug discovery. Based on our analysis, the results of AA derivatives show good and accepted prediction of physicochemical properties in comparison to Lipinski's RO5, Ghose filter, Vebers's, Egan's, and Muegge's rules for oral bioavailable drugs and in comparison with the physicochemical properties of marketed anticancer drugs. The correlation of the results of the accepted physicochemical properties with the predicted ADMET results shows that only seven AA derivatives, AA11, AA22, AA24, AA25, AA95, AA97, and AA98, fall within the accepted range of the parameters of ADMET. However, the docking studies of the finally scrutinized 17 derivatives were investigated, as they acquire adequate pharmacokinetic properties for oral bioavailability.

3.5. Molecular Docking Studies {#sec3.5}
------------------------------

Molecular docking studies were analyzed for exploring the interaction mechanism between the receptor sites and inhibitors.^[@ref38]^ In the field of drug discovery, the prediction of interactions between molecules and their targets has a great importance. One can easily find out the mechanisms of selectivity by the docking of molecules with protein targets.^[@ref39]−[@ref41]^ In this work, the activities of anacardic derivatives were screened out against the target cyclin-dependent kinase 2 (PDB ID: 1w98). Cyclin-dependent kinase 2, also known as cell-division protein kinase 2, is an enzyme usually found in humans. It is encoded as CDK2 gene. It is necessary for cell cycle progression and mostly overexpressed in cancer cells. By using the SwissDock Web server (<http://www.swissdock.ch>), molecular docking of all the filtered 17 AA derivatives (AA11, AA12, AA16, AA20--AA25, AA33, AA34, AA72, AA75, AA95, AA96, AA97, and AA98) was performed against human cyclins or cell division protein kinase 2 (PDB ID: 1w98).^[@ref42]^ For the cell cycle, cyclins are essential proteins. Perturbation of the cyclin function can cause cancer formation. The structural factors and atomic coordinates of the protein cyclin were deposited.^[@ref43]^ The results pointed out that the filtered AA derivatives form conventional bonds with the receptor sites. Different parameters like FF (kcal/mol), Δ*G* (Gibb's free energy), ligand solvation energy, hydrogen bonding (interactions), and so forth of docking were analyzed. On the basis of FF and cluster formation, all suitable binding modes were analyzed.^[@ref44]^ All the output clusters were ranked in accordance with hydrogen bonding (interactions) and the FF score. A cluster rank "0" is considered to be the best FF score. A molecule is said to have more favorable binding modes with a better fit if the FF score shows greater negative value.^[@ref45]^ The docked conformations having the lowest binding energy were selected for discussion.^[@ref46]^ However, for the most favorable interaction, if a molecule has a small docking score, then it is said to have a higher binding affinity of ligands for a particular receptor.^[@ref47]^ The FF score, binding affinity, and active residues of docked conformations are depicted in [Table [7](#tbl7){ref-type="other"}](#tbl7){ref-type="other"}. Out of 17 docked complexes, the derivatives AA20, AA21, and AA22 show three hydrogen-bonding interactions with the target residues, whereas the derivative AA75 shows the maximum FF score (−3054.45) with one hydrogen-bonding interaction with LEU 2.418 Å. The docked conformations of 17 AA derivatives and the target (PDB ID: 1w98) are presented in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}.

![Docked ligands with target-1W98: (a) AA11, (b) AA12, (c) AA16, (d) AA20, (e) AA21, (f) AA22 (g) AA23, (h) AA24, (i) AA25 (j) AA33, (k) AA34, (l) AA72 (m) AA75, (n) AA95, (o) AA96, (p) AA97, and (q) AA98.](ao9b04398_0004){#fig4}

###### Results of Docking of AA Derivatives with 1W98

  Der. docked with 1W98   Δ*G*       deltaGligsolvpol   FF (kcal/mol)   energy      (protein···ligand) sites type/binding residue/H-bonding distance
  ----------------------- ---------- ------------------ --------------- ----------- ------------------------------------------------------------------
  AA11                    --7.2239   --9.9810           --3029.41       7.2787      N--H···**O**/GLN174/2.345 Å
                                                                                    **O···H**/LYS170/2.344 Å
  AA12                    --7.5062   --11.9606          --3014.64       21.7154     N--H···**O**/GLN174/2.359 Å
                                                                                    **O···H**/LYS170/2.155 Å
  AA16                    --6.3474   --7.9222           --3040.32       --9.9220    **O···H**/LEU113/2.618 Å
                                                                                    N--H···**O**/LEU113/2.256 Å
  AA20                    --6.8278   --16.5444          --3045.13       7.2032      **O···H**/LEU277/1.953 Å
                                                                                    **O···H**/TYR112/2.301 Å
                                                                                    **O···H**/GLU109/2.646 Å
  AA21                    --6.5128   --8.9698           --3018.17       16.201      **O···H**/LYS170/2.013 Å
                                                                                    **O···H**/THR171/2.575 Å
                                                                                    N--H···**O**/GLN174/2.523 Å
  AA22                    --7.8004   --19.1000          --3041.91       5.6960      **O···H**/LEU277/2.19 Å
                                                                                    **O···H**/GLU109/2.508 Å
                                                                                    **O···H**/GLU278/2.478 Å
  AA23                    --6.7354   --7.7501           --3035.65       --1.1662    **O···H**/THR171/2.481 Å
  AA24                    --6.3980   --10.9386          --3038.37       --3.4394    **O···H**/GLU109/2.562 Å
                                                                                    **O···H**/GLU109/2.310 Å
  AA25                    --6.9110   --11.2838          --3049.17       --12.0395   **O···H**/LYS170/2.512 Å
                                                                                    N--H···**O**/GLN174/2.393 Å
  AA33                    --7.1697   --6.6352           --3034.61       --4.6578    **O···H**/THR171/2.150 Å
  AA34                    --7.3850   --7.5994           --3031.71       --6.3850    **O···H**/LYS170/2.586 Å
  AA72                    --7.8560   --7.7790           --3020.07       --4.9699    **O···H**/THR202/2.302 Å
  AA75                    --7.5994   --7.5706           --3054.45       --28.0006   N--H···**N**/LEU113/2.418 Å
  AA95                    --6.2015   --4.3915           --3006.90       16.0120     N--H···**O**/ARG114/2.275 Å
  AA96                    --6.4796   --4.7592           --3008.22       15.3224     N--H···**O**/ASN74/2.606 Å
  AA97                    --6.4855   --6.0909           --2787.35       240.0530    N--H···**O**/LEU113/2.580 Å
  AA98                    --6.4602   --7.4286           --3010.43       11.7630     N--H···**O**/ARG114/2.472 Å

4. Conclusions {#sec4}
==============

For the drug designing and development process, the evaluation of pharmacokinetic and physicochemical properties is the primary task. In the present work, 100 AA derivatives were evaluated with the in silico screening procedure based on ADME parameters. The results show the optimal property range (covering 100 derivatives of AA) used to select oral bioavailable drugs. From the evaluation of in silico computational studies including ADME, the pkCSM data revealed that 80% of the selected AA derivatives in this work have shown high Caco2 permeability of log *P*~app~ \<0.9 and 25% of the AA derivatives were found as P-gp efflux substrates with low-to-moderate clearance rates. The docking results of the finally scrutinized 17 derivatives which were allowed to dock with the anticancer target cyclin-dependent kinase 2 reveal that the AA derivatives are strongly bound with the targets and inhibit the target through hydrogen-bonding interactions. Better bioactivity score, drug adsorption ability, and drug-likeness of these derivatives pave a new research arena with vegetable feedstocks. Rege et al. have recently explored the dual functionality of certain AA derivatives for efficient paclitaxel delivery in breast cancer therapy.^[@ref48],[@ref49]^ The higher binding affinity results of the 17 AA derivatives with the anticancer target (PDB ID: 1W98) and their in silico pharmacokinetic studies would definitely provide motivation to biochemists for performing further wet lab and clinical evaluations.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.9b04398](https://pubs.acs.org/doi/10.1021/acsomega.9b04398?goto=supporting-info).Chemical structures of alkyl chain-modified AA derivatives (labeled from 1 to 29); chemical structures of alkyl chain- and functional group-modified AA derivatives labeled from 30 to 49; chemical structures of alkyl chain- and functional group-modified AA derivatives labeled from 50 to 76; chemical structures of alkyl chain- and functional group-modified AA derivatives labeled from 77 to 100; BOILED-Egg model of AA1--AA100 derivatives; important computed physicochemical properties for AA1--AA100; important computed ADMET properties for AA1--AA100 derivatives; and computed safety end points for AA1--AA100 derivatives ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b04398/suppl_file/ao9b04398_si_001.pdf))
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